E
Elizabeth Mickiewicz
Publications - 4
Citations - 2850
Elizabeth Mickiewicz is an academic researcher. The author has contributed to research in topics: Exemestane & Tamoxifen. The author has an hindex of 3, co-authored 4 publications receiving 2782 citations.
Papers
More filters
Journal ArticleDOI
A Randomized Trial Of Exemestane After Two To Three Years Of Tamoxifen Therapy In Postmenopausal Women With Primary Breast Cancer.
R. C. Coombes,Emma Hall,Lorna Gibson,Robert Paridaens,Jacek Jassem,Thierry Delozier,Stephen E. Jones,Isabel Alvarez,Gianfilippo Bertelli,Olaf Ortmann,Alan S. Coates,Emilio Bajetta,D. Dodwell,Robert E. Coleman,Lesley Fallowfield,Elizabeth Mickiewicz,Jens O. Andersen,Per Eystein Lønning,G. Cocconi,Alan L Stewart,N Stuart,Claire Snowdon,M. Carpentieri,Giorgio Massimini,Judith M Bliss +24 more
TL;DR: Exemestane therapy after two to three years ofTamoxifen therapy significantly improved disease-free survival as compared with the standard five years of tamoxIFen treatment.
Journal ArticleDOI
Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial
R. C. Coombes,Lucy Kilburn,Claire Snowdon,Robert Paridaens,Robert E. Coleman,Stephen E. Jones,Jacek Jassem,Cjh van de Velde,Thierry Delozier,Isabel Alvarez,L. Del Mastro,Olaf Ortmann,K Diedrich,Alan S. Coates,Emilio Bajetta,Stig Holmberg,D. Dodwell,Elizabeth Mickiewicz,Jens O. Andersen,Per Eystein Lønning,G. Cocconi,John F. Forbes,Monica Castiglione,N Stuart,Alan L Stewart,Lesley Fallowfield,Gianfilippo Bertelli,Emma Hall,R. G. Bogle,M. Carpentieri,E Colajori,M Subar,E. Ireland,Judith M Bliss +33 more
TL;DR: The results suggest that early improvements in disease-free survival noted in patients who switch to exemestane after 2-3 years on tamoxifen persist after treatment, and translate into a modest improvement in overall survival.
Journal ArticleDOI
Activity of Exemestane in Metastatic Breast Cancer After Failure of Nonsteroidal Aromatase Inhibitors: A Phase II Trial
Per Eystein Lønning,Emilio Bajetta,Robin Murray,Michèle Tubiana-Hulin,Peter D. Eisenberg,Elizabeth Mickiewicz,Luigi Celio,Paula Pitt,Monica M. Mita,Neil K. Aaronson,Camilla Fowst,Alexei Arkhipov,Enrico Di Salle,Anna Polli,Giorgio Massimini +14 more
TL;DR: Exemestane 25 mg once daily seems to be an attractive alternative to chemotherapy for the treatment of patients with metastatic breast cancer after multiple hormonal therapies have failed.
Activity o f E xemestane i n M etastatic B reast C ancer After F ailure o f N onsteroidal A romatase I nhibitors: A P hase I I T rial
Emilio Bajetta,Robin Murray,Peter D. Eisenberg,Elizabeth Mickiewicz,Luigi Celio,Paula Pitt,Monica M. Mita,Neil K. Aaronson,Camilla Fowst,Alexei Arkhipov,Anna Polli,Giorgio Massimini +11 more
TL;DR: Exemestane 25 mg once daily seems to be an attractive alternative to chemotherapy for the treatment of patients with metastatic breast cancer after multiple hormonal therapies have failed.